Lanreotide
Specialist research
Clinical research includes acromegaly, carcinoid syndrome, and somatostatin receptor positive enteropancreatic neuroendocrine tumors.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Lanreotide?
Lanreotide is a synthetic somatostatin analogue peptide used in endocrine and neuroendocrine research focusing on somatostatin receptor biology; the catalogue label denotes research grade lanreotide material.
Which research context has Lanreotide been associated with?
Lanreotide is associated with specialist translational research as a somatostatin analogue peptide, with clinical studies in acromegaly, carcinoid syndrome symptom management, and somatostatin receptor positive enteropancreatic neuroendocrine tumour imaging and therapy contexts.
What documentation is available for Lanreotide?
Lanreotide: Batch documents are not yet linked on this site. For this synthetic somatostatin analogue peptide expected evidence includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity criteria; peptide content, counterion and residual solvent/water details; and validated potency/assay methods for batch release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Lanreotide?
Lanreotide: Storage depends on the documented supplied presentation; as a synthetic somatostatin analogue peptide confirm dry/lyophilised versus solution form, counterion and concentration, solvent or buffer composition, pH and container closure interactions and ensure cyclic/conformational integrity and oxidation liability are assessed for stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.